Adaptive Radiation Boost for Rectal Cancer (ARBOR) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

The goal of this clinical trial is to find out if giving extra adaptive radiation therapy after standard chemoradiation treatment is safe and helpful for people with rectal cancer.

  • By

  • September 4, 2026

  • 3 min

Share

  • 1

    The ARBOR trial investigates the safety and efficacy of adaptive radiation therapy after standard chemoradiation for rectal cancer.

  • 2

    Participants will receive standard treatment followed by adaptive radiation based on MRI scans to target aggressive cancer cells.

  • 3

    Inclusion criteria require histologically confirmed rectal adenocarcinoma and specific staging parameters.

  • 4

    Exclusion criteria include prior treatment for rectal cancer, anal canal involvement, and uncontrolled intercurrent illnesses.

  • 5

    The trial aims to reduce side effects while protecting healthy tissue during treatment.

Original Source(s)

Adaptive Radiation Boost for Rectal Cancer (ARBOR)

  • by

  • September 4, 2026

Related Content

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

  • by

  • September 4, 2026

  • 4 min
Therapy-induced immunoediting and the evolution of cancer immune escape

Fellowship-Trained Neuro-Oncologist Nishika Karbhari, M.D., Joins Baptist Health Herbert Wertheim Cancer Institute

Fellowship-trained neuro-oncologist Nishika Karbhari, M.D., has joined Baptist Health Herbert Wertheim Cancer Institute.

  • by

  • September 3, 2026

  • 2 min